

1 **Combined association of obesity and other cardiometabolic diseases with severe COVID-19**
2 **outcomes: a nationwide cross-sectional study of 21,773 Brazilian adult and elderly inpatients**

3 Natanael J Silva, MSc^{1,2}; Rita C Ribeiro-Silva, PhD^{1,2,3}; Andréa JF Ferreira, MSc^{1,2,4}; Camila SS
4 Teixeira, MSc^{1,2,4}; Aline S Rocha, MSc^{1,2,3}; Flávia Jôse O Alves, MSc^{1,2,4}; Ila R Falcão, PhD²;
5 Elizabete J Pinto, PhD^{2,5}; Carlos Antônio ST Santos, PhD^{1,2,6}; Rosemeire L Fiaccone, PhD^{1,2,7}; Maria
6 Yury T Ichihara, MD PhD^{1,2}; Enny S Paixão, PhD^{1,2,8}; Mauricio L Barreto, MD PhD^{1,2,4}

7 ¹ Rede CoVida, Salvador, BA, Brazil

8 ² Centre for Data and Knowledge Integration for Health, Oswaldo Cruz Foundation, Salvador, BA, Brazil

9 ³ School of Nutrition, Federal University of Bahia, Salvador, BA, Brazil

10 ⁴ Institute of Collective Health, Federal University of Bahia, Salvador, BA, Brazil

11 ⁵ Center for Health Sciences, Federal University of Recôncavo da Bahia, Santo Antônio de Jesus, BA, Brazil

12 ⁶ Department of Exact Sciences, State University of Feira de Santana, Feira de Santana, BA, Brazil

13 ⁷ Institute of Mathematics and Statistics, Federal University of Bahia, Salvador, BA, Brazil

14 ⁸ Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK

15 **Corresponding author:** Natanael J Silva. Centre for Data and Knowledge Integration for Health,
16 Oswaldo Cruz Foundation. Edf. Tecnocentro, Sl 315. Rua Mundo, 121. Trobogy, Salvador, BA,
17 41745-715, Brazil. Phone number: +55 79 99839-3991. Email: <silva_natanael@hotmail.com>.

18 **Keywords:** Obesity, COVID-19, SARS-CoV-2, Hospitalization, Mortality.

19 **Word count:** 3,204

20 **Abstract**

21 **Objectives:** To investigate the combined association of obesity, diabetes mellitus (DM), and
22 cardiovascular disease (CVD) with severe COVID-19 outcomes in adult and elderly inpatients.

23 **Design:** Cross-sectional study based on registry data from Brazil's influenza surveillance system.

24 **Setting:** Public and private hospitals across Brazil.

25 **Participants:** Eligible population included 21,942 inpatients aged ≥ 20 years with positive RT-PCR
26 test for SARS-CoV-2 until Jun 9th, 2020.

27 **Main outcome measures:** Severe COVID-19 outcomes were non-invasive and invasive mechanical
28 ventilation use, ICU admission, and death. Multivariate analyses were conducted separately for adults
29 (20-59 years) and elders (≥ 60 years) to test the combined association of obesity (without and with
30 DM and/or CVD) and degrees of obesity with each outcome.

31 **Results:** A sample of 8,848 adults and 12,925 elders were included. Among adults, obesity with DM
32 and/or CVD showed higher prevalence of invasive (PR 3.76, 95%CI 2.82-5.01) and non-invasive
33 mechanical ventilation use (2.06, 1.58-2.69), ICU admission (1.60, 1.40-1.83), and death (1.79, 1.45-
34 2.21) compared with the group without obesity, DM, and CVD. In elders, obesity alone (without DM
35 and CVD) had the highest prevalence of ICU admission (1.40, 1.07-1.82) and death (1.67, 1.00-2.80).
36 In both age groups, obesity alone and combined with DM and/or CVD showed higher prevalence in
37 all outcomes than DM and/or CVD. A dose-response association was observed between obesity and
38 death in adults: class I 1.32 (1.05-1.66), class II 1.41 (1.06-1.87), and class III 1.77 (1.35-2.33).

39 **Conclusions:** The combined association of obesity, diabetes, and/or CVD with severe COVID-19
40 outcomes may be stronger in adults than in elders. Obesity alone and combined with DM and/or CVD
41 had more impact on the risk of COVID-19 severity than DM and/or CVD in both age groups. The
42 study also supports an independent relationship of obesity with severe outcomes, including a dose-
43 response association between degrees of obesity and death in adults.

44 **Article summary**

45 Strengths and limitations of this study:

- 46 • This is the first study that describes the independent and combined relationship of obesity
47 with COVID-19 severity in Brazil, one of the biggest epicenters of the pandemic worldwide.
- 48 • The study was based on registry data of a large nationwide sample of patients admitted, due
49 to severe SARS-CoV-2 infection, to public and private hospitals across the country.
- 50 • The large sample size and data availability allowed us to analyze the combined association of
51 obesity, diabetes and cardiovascular disease with severe COVID-19 outcomes, separately by
52 age groups and controlled by important confounding variables, e.g. underlying comorbidities.
- 53 • The cross-sectional study design does not allow causal inference, and generalization of results
54 must be cautious since only hospitalized cases of severe COVID-19 were included.
- 55 • As the study used routinely collected data, which has not been designed primarily for research
56 purposes, it may bring well-known limitations related to missing, underestimation, and
57 potential misclassification.

58 **Introduction**

59 The coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory
60 syndrome coronavirus 2 (SARS-CoV-2), as of 13 May 2021, has already reached more than 160
61 million infected people and more than 3.3 million deaths in all continents.¹ Individuals with advanced
62 age and chronic diseases, including cardiometabolic diseases, are considered groups at major risk for
63 complications and severe illness from COVID-19.^{2,3} Obesity has been shown as an independent risk
64 factor for COVID-19 disease.⁴⁻⁶ High body mass index (BMI) has been mentioned as a significant
65 risk factor for COVID-19, according to early clinical reports from China,⁷ Italy,⁸ France,⁹ Mexico,¹⁰
66 and United States of America.¹¹ Several studies have demonstrated that obesity is leading to
67 considerably worse COVID-19 outcomes, especially greater risk of hospital and intensive care unit
68 (ICU) admission, invasive mechanical ventilation, and death.¹¹⁻¹⁴

69 The COVID-19 pandemic is rapidly spreading worldwide, especially in the Americas, where obesity
70 is already a prevalent and important public health problem.¹⁵⁻¹⁶ Brazil is currently one of the biggest
71 epicenters of the COVID-19 pandemic worldwide, with more than 15.2 million cases and 425
72 thousand deaths until May 13, 2021.¹ In 2018, the prevalence of adult overweight and obesity in
73 Brazil was estimated at 55.7% and 19.8%, respectively.¹⁷ This obesogenic profile of the Brazilian
74 population contributes, among other factors, to the high prevalence of obesity-related diseases such
75 as type 2 diabetes mellitus (DM) and cardiovascular diseases (CVD), in the country.¹⁸ The fact that
76 individuals with obesity also have more comorbidity diseases, which are either risk factors for
77 COVID-19 severity and death, makes obesity particularly ominous in COVID-19 disease.¹⁰⁻¹³

78 Several characteristics that can influence the clinical evolution of individuals infected with COVID-
79 19, such as obesity, have been independently documented.^{5-6,19} However, evidence is yet unclear on
80 the combined effect that obesity and obesity-related comorbidities play in COVID-19 severity,
81 especially, in different age groups. We aimed in this study to investigate the combined association of
82 obesity, diabetes, and cardiovascular disease with mechanical ventilation use, ICU admission, and

83 death in a large sample of adult and elderly patients hospitalized with COVID-19 in Brazil. We also
84 explored the independent association between degrees of obesity and the mentioned outcomes.

85 **Methods**

86 *Study Design and Population*

87 This is a cross-sectional study based on registry data from SIVEP-Gripe (Sistema de Informação de
88 Vigilância Epidemiológica da Gripe), an influenza surveillance system of Brazil's Ministry of Health.
89 The study used the publicly available dataset of SIVEP-Gripe, which includes de-identified data on
90 cases of severe acute respiratory syndrome across public and private hospitals in Brazil.²⁰ These data
91 were obtained through the Rede CoVida's integrated data platform that has been built with official,
92 open, and authorized data for the production of knowledge about the COVID-19 pandemic. Our study
93 population was composed of patients aged 20 years or older, hospitalized for severe acute respiratory
94 syndrome, with positive RT-PCR test for SARS-CoV-2, and final diagnosis for COVID-19 until Jun
95 9th, 2020. Only cases with complete data on demographic characteristics and comorbidities and
96 plausible BMI values were included in the study.

97 The study was conducted according to the guidelines laid down in the Declaration of Helsinki. As the
98 study exclusively used publicly available de-identified data, ethics approval by a research ethics
99 committee and informed consent are waived per Resolution n. 466/2012 of the National Health
100 Council of Brazil's Commission of Ethics in Research.

101 *Exposure Variable*

102 Obesity was defined as BMI equal to or greater than 30 kg/m², according to the cutoff points proposed
103 by the World Health Organization²¹ and the Pan American Health Organization²² for adults and
104 elders, respectively. BMI was calculated by health professionals in the hospital from directly
105 measured or patient self-reported height and weight. Guidelines for the collection and analysis of
106 anthropometric data in health services have been previously standardized by the Ministry of Health.²³
107 BMI values <12 or >70 kg/m² were considered implausible and excluded.²⁴ Information on the

108 existence of diabetes and any chronic cardiovascular disease was obtained from dichotomous
109 questions (yes/no), which were answered based on patient or family's report or medical diagnosis.

110 We created a polytomous four-category variable to evaluate the separate and combined exposure of
111 obesity, diabetes and cardiovascular disease: none/reference (no existence of obesity, diabetes and
112 cardiovascular disease), OB (only existence of obesity), OB + DM and/or CVD (existence of obesity
113 with diabetes and/or cardiovascular disease), and DM and/or CVD (existence of diabetes and/or
114 cardiovascular disease). We also analyzed obesity in adults according to the following degrees of
115 severity based on WHO reference²¹: no obesity ($<30 \text{ kg/m}^2$), obesity class I ($\geq 30\text{-}34.9 \text{ kg/m}^2$), obesity
116 class II ($\geq 35\text{-}39.9 \text{ kg/m}^2$), and obesity class III ($\geq 40 \text{ kg/m}^2$). Due to the unavailability of BMI cutoff
117 points to classify the degree of obesity in elders, this analysis was only performed for adults.

118 ***Outcome Variables***

119 The severe COVID-19 outcomes were mechanical ventilation use, ICU admission, and death.
120 Information on the use of mechanical ventilation by the patient was obtained and analyzed as a
121 polytomous three-category variable (no use/ use of non-invasive ventilation/ use of invasive
122 ventilation). ICU admission was obtained and analyzed as a dichotomous variable (no/ yes). Death
123 was analyzed as a dichotomous variable based on the patient's endpoint outcome (cure/ death).

124 ***Covariates***

125 Demographic and comorbidity information were selected as descriptive and confounding variables.²
126 Age in years was calculated from birth and notification dates. Sex was obtained as a dichotomous
127 variable (female/ male). The preexistence of each comorbidity was also obtained as a dichotomous
128 variable (no/ yes): chronic pulmonary disease, asthma, chronic kidney disease, chronic hematologic
129 disease, neurological disease, chronic liver disease, and immunodeficiency/ immunosuppression.

130 ***Statistical Analysis***

131 All analyses were subdivided into adults (≥ 20 and < 60 years) and elders (≥ 60 years). For descriptive
132 analyses, absolute and relative frequencies were calculated for the demographic and comorbidity

133 variables according to the main exposure variable. Multinomial logistic regression models were
134 conducted to test the association of obesity (without and with diabetes and/or CVD) with non-invasive
135 and invasive mechanical ventilation use. To test the association of this exposure variable with ICU
136 admission and death, simple logistic regression models were performed. Same models were analyzed
137 considering the degree of obesity as the main exposure variable for adults. Crude and adjusted
138 estimates were interpreted based on the prevalence ratio (PR) and 95% confidence intervals (95%CI).
139 These estimates were obtained from logistic models using delta method, function ‘prLogisticDelta’,
140 which is implemented in R and available in the package ‘prLogistic’. Adjusted models included the
141 following list of confounding variables: sex, age (years), and the preexistence of chronic pulmonary
142 disease, asthma, kidney disease, hematologic disease, neurological disease, liver disease, and
143 immunodeficiency/ immunosuppression. The models that tested the degrees of obesity were also
144 adjusted for DM and CVD. All analyses were performed using Stata version 15.1 (Stata Corporation,
145 College Station, USA) and R version 3.6.1 (R Foundation for Statistical Computing, Austria).

146 *Patient and Public Involvement*

147 As the study exclusively used publicly available de-identified data, it was not possible to involve
148 patients or the public in the design, or conduct, or reporting, or dissemination plans of our research.

149 **Results**

150 During the study period, 21,942 individuals registered in the SIVEP-Gripe were ≥ 20 years old,
151 hospitalized, tested positive for SARS-CoV-2, and had complete demographic and comorbidity
152 information (**Figure 1**). Of these, 169 (0.8%) were excluded due to implausible values of BMI. Of
153 the 21,773 individuals included in the study, 8,848 (40.3%) were adults aged between 20-59 years,
154 and 12,925 (59.6%) were elders aged 60 years or older. Since some patients were still hospitalized
155 on the study endpoint date, information for some outcomes were incomplete. The study samples
156 included in the analysis of each outcome were 8,075 adults and 11,829 elders for mechanical
157 ventilation, 8,414 adults and 12,222 for ICU admission, and 6,565 adults and 9,943 elders for death.

158 Based on demographic and clinical characteristics, the analytical samples in each outcome were very
159 similar to the overall study population and the excluded samples (**Supplementary Table 1**).

160 The prevalence of obesity was 9.7% in adults and 3.5% in elders. The frequency of obesity without
161 and with DM and/or CVD was respectively 4.6% and 5.1% in adults and 0.7% and 2.8% in elders.
162 Non-invasive and invasive mechanical ventilation were respectively required by 45.0% and 21.2%
163 of adults and 47.0% and 30.0% of elders. ICU admission was needed by 35.4% of adults and 43.6%
164 of elders. Death occurred in 31.1% of adult and 63.0% of elderly patients (**Table 1-2**).

165 In the adjusted analyses for adults, obesity alone (without DM and CVD) was associated with an
166 increased prevalence of invasive (PR 2.69, 95%CI 1.98-3.65) and non-invasive mechanical
167 ventilation need (PR 2.13, 95%CI 1.64-2.78), ICU admission (PR 1.31, 95%CI 1.13-1.53), and death
168 (PR 1.33, 95%CI 1.05-1.69) when compared with the group without obesity, DM, and CVD. Obesity
169 with DM and/or CVD was associated with an even higher prevalence of invasive mechanical
170 ventilation (PR 3.76, 95%CI 2.82-5.01) and non-invasive ventilation use (PR 2.06, 95%CI 1.58-2.69),
171 ICU admission (PR 1.60, 95%CI 1.40-1.83), and death in adults (PR 1.79, 95%CI 1.45-2.21). The
172 subgroup of adults with DM and/or CVD showed in general the lowest prevalence ratios for all
173 analyzed outcomes than the subgroups with the presence of obesity alone or combined (**Table 3**).

174 Among elders, obesity without DM and CVD increased independently the prevalence of ICU
175 admission by 40% (95%CI 1.07-1.82) and death by 67% (1.00-2.80). To a lesser extent, obesity with
176 DM and/or CVD was also associated with an increased prevalence of invasive mechanical ventilation
177 need (PR 1.66, 95%CI 1.22-2.27), ICU admission (PR 1.37, 95%CI 1.19-1.59), and death (PR 1.39,
178 95%CI 1.07-1.80). Elders with DM and/or CVD had the lowest prevalence ratios for the analyzed
179 outcomes than the subgroups of elders with obesity alone or combined (**Table 3**).

180 In the analyses by the degree of obesity, we did not observe much difference in the prevalence of
181 adverse outcomes, except for the prevalence of death that increased with the severity of obesity: Class
182 I 1.32 (95%CI 1.05-1.66), Class II 1.41 (1.06-1.87), and Class III 1.77 (1.35-2.33) (**Table 4**).

183 **Discussion**

184 This is the first study that describe the relationship of obesity and COVID-19 in Brazil, based on a
185 large nationwide sample of adults and elders tested positive for SARS-CoV-2 and admitted to public
186 and private hospitals. Our results highlights that obesity with DM and/or CVD was associated with
187 higher rates of invasive mechanical ventilation use, ICU admission, and death in adults, while obesity
188 alone (without DM and CVD) was associated with higher rates of ICU admission and death among
189 elders. In both age groups, obesity alone and obesity combined with DM and/or CVD had more
190 impact on the risk of all severe COVID-19 outcomes than the subgroup with DM and/or CVD. The
191 study also supports the independent association of obesity with the analyzed outcomes and a dose-
192 response association between degrees of obesity and death in adults.

193 Some mechanisms related to the role of obesity and related diseases in worsening the clinical
194 condition of patients affected by SARS-CoV-2 have been pointed out: i) greater body weight causes
195 less elasticity of the chest wall and less total compliance of the respiratory system, leading to a
196 restriction of the ventilation and the excursion of the diaphragm, making difficult the airway
197 management in patients with obesity;²⁵ ii) obesity is associated with sleep apnea syndrome and
198 chronic obstructive pulmonary disease, which lead to surfactant dysfunction and impede the proper
199 functioning of the airways;²⁶ iii) obesity is a metabolic and inflammatory disease, which is associated
200 with the development or worsening of other chronic and endocrine comorbidities (e.g. type 2 diabetes,
201 hypertension, dyslipidemia and CVD) that can modify innate and adaptive immune responses,
202 making the immune system more vulnerable to infections and less responsive to antivirals and
203 antimicrobial drugs;¹⁶ iv) glycemic decompensation, common in patients with obesity, is associated
204 with impaired ventilation function.²⁶

205 It is important to note that the COVID-19 pandemic imposes a double burden of disease, especially
206 among the elderly individuals, since the prevalence of diabetes, hypertension, cardiovascular
207 diseases, and other comorbidities associated with COVID-19 severity increases with age.^{3,27}
208 However, our study suggests that obesity combined with diabetes and/or cardiovascular disease may

209 offer higher risk of COVID-19 severity for adults although the overall prevalence of diseases and
210 rates of ICU admission and mortality were higher in elders. Obesity alone seemed to provide higher
211 risk of severe outcomes, especially death, in elders.

212 Few studies to-date have explored the combined and additional effect of obesity on COVID-19
213 severity.^{13,28} A study investigated the patterns of multimorbidity among fatal cases of COVID-19 in
214 Colombia.²⁸ Similar to our study, the authors found that obesity alone or with other diseases was
215 associated with a higher risk of COVID-19 fatality among young people. Furthermore, a population-
216 based study in Mexico observed that the addition of obesity to any number of comorbidities
217 significantly increased the risk of COVID-19 lethality.¹³ Using a causally ordered mediation analysis,
218 this study also found that 49.5% of the effect of diabetes on COVID-19 lethality was mediated by
219 obesity, particularly in early-onset cases < 40 years of age.

220 Other studies also suggest that obesity is independently associated with severe outcomes of COVID-
221 19, regardless of age and other associated comorbidities.¹¹⁻¹⁴ A large study in Mexico¹³ showed that
222 patients with obesity had higher rates of ICU admission and were more likely to be intubated in
223 relation to patients without obesity. This study also found a five-fold increased risk of mortality due
224 to COVID-19 in patients with obesity.¹³ In a hospital-based study in France, it was observed that BMI
225 > 35 kg/m² was associated with the need for invasive mechanical ventilation.¹⁴

226 Few studies to-date have similarly found a dose-response association between degrees of obesity and
227 COVID-19 death.²⁹ Based on care records of 17,278,392 UK adults, the study showed that the risk
228 of COVID-19 death increases independently with the degree of obesity: 30-34.9 kg/m² (HR 1.05),
229 35-39.9 kg/m² (1.40), and ≥ 40 kg/m² (2.66).²⁹ Other studies have evidenced the association of obesity
230 with COVID-19 complications and death among adults.^{12,30} A hospital-based study in New York City
231 showed that morbid obesity (BMI ≥ 40 kg/m²) is strongly and independently associated with death in
232 hospitalized patients younger than 50 years.³⁰ Another study in New York City found a similar dose-
233 response relationship between degrees of obesity and acute and critical care.¹² Patients less than 60
234 years old with BMI between 30 and 34.9 kg/m² (obesity class I) were 2.0 and 1.8 times more likely

235 to be respectively admitted for acute care (general hospital admission) and critical care (ICU
236 admission or invasive ventilator) compared to individuals with BMI < 30 kg/m². Patients of the same
237 age group with BMI ≥ 35 kg/m² (obesity class II and III) showed 2.2 and 3.6 more chances of being
238 hospitalized for acute and critical care, respectively.¹²

239 *Strengths and limitations*

240 One of the greatest strengths of the study was the use of SIVEP-Gripe dataset. Because severe acute
241 respiratory syndrome is a condition of compulsory notification in both public and private hospitals,³¹
242 we have a nationwide representative sample of patients hospitalized for severe COVID-19 in Brazil.
243 In addition, the large sample sizes allowed us to analyze adults and elders separately, as well as the
244 degrees of obesity which dose-response association with death was evidenced. The availability of
245 important confounding variables (sex, age, and preexisting comorbidities) to control the estimated
246 associations, as well as hospital outcomes and mortality of COVID-19, was another differential of
247 the study. Only patients with positive RT-PCR test for SARS-CoV-2 and final diagnosis for COVID-
248 19 were included which gives greater precision on the studied population. The availability and use of
249 data from health surveillance systems may be a lesson from Brazil that other countries can learn for
250 obtaining routine and timely data to guide health systems and research in preparing and responding
251 to pandemics before and during their course.

252 The study also has some limitations that must be considered. Because this is a cross-sectional study,
253 a causal association cannot be inferred. As we used routinely collected data, which has not been
254 designed primarily for research purposes, it may bring well-known limitations related to missing,
255 underestimation, and potential misclassification. Obesity prevalence may have been underestimated
256 due to the completeness of obesity and BMI data. Previous studies using SIVEP-Gripe data have also
257 found a low prevalence of obesity in this population.^{32,33} Better routine collection of height and weight
258 data is still needed in clinical practice. Also, we believe that health professionals have adopted more
259 the one method to collect weight and height information for BMI calculation, such as the patient's
260 self-report and direct measure. Therefore, in addition to BMI which implausible values were checked

261 and excluded, the classification of obesity was also confirmed from a dichotomous variable on the
262 presence of obesity (no/yes). Although it is known that BMI does not distinguish between fat and
263 lean body mass, and thus may lead to misclassification bias, BMI has been shown as a strong predictor
264 of excess body fat and has been widely used in epidemiological studies.¹⁵ Information for some
265 outcomes were incomplete because some patients were still hospitalized on the study endpoint date.
266 However, that did not represent a potential selection bias to our study. The analytical samples in each
267 outcome had similar demographic and clinical characteristics than the overall study population and
268 the excluded samples (Supplementary Table 1). Data on ethnicity/race was very incomplete, and thus
269 was not included in the analysis. Additional studies are needed to further explore the relationship
270 between socioeconomic characteristics and obesity in severe disease. Finally, the generalization of
271 results must be cautious since the study included only hospitalized cases of COVID-19.

272 **Conclusions**

273 The combined association of obesity, diabetes, and/or cardiovascular disease with severe COVID-19
274 outcomes, especially ICU admission and death, may be stronger in adult than in elderly inpatients. In
275 both age groups, obesity alone and obesity combined with DM and/or CVD had more impact on the
276 risk of all severe COVID-19 outcomes than the subgroup with DM and/or CVD. The study also
277 supports an independent relationship of obesity with the severe outcomes, including a dose-response
278 association between degrees of obesity and death in adults. These findings suggest important
279 implications for the clinical care of patients with obesity and severe COVID-19, such as the increased
280 need of critical care and higher risk of death among these patients. Our study also supports the
281 inclusion of people with obesity, independently of other preexisting comorbidities and age, in the
282 high-risk and vaccine priority groups for protection from SARS-CoV-2 infection.

283 **Acknowledgments**

284 The authors thank the members of Rede CoVida's Epidemiology & Information Group for the work
285 of identifying and collecting data related to COVID-19.

286 **Author Contributions**

287 NJS, RCRS, and RLF designed the study and analysis strategy. NJS, CASTS, and MYTI obtained,
288 documented, and described the data. AJFF, CSST, ASR, FJOA, and IRF carried out the literature
289 search. NJS and EJP performed the data analysis. NJS, RCRS, AJFF, CSST, ASR, FJOA, IRF, ESP
290 and MLB contributed to data interpretation. NJS, AJFF, CSST, ASR, FJOA, and IRF drafted the
291 manuscript. RCRS, ESP, MYTI, and MLB critically revised the manuscript. All authors read and
292 approved the final manuscript.

293 **Funding**

294 All authors are affiliated to the Centre for Data and Knowledge Integration for Health (CIDACS) that
295 is funded and supported by MCTI/ CNPq/ MS/ SCTIE/ Decit/ Bill & Melinda Gates Foundation's GCE
296 Brazil (OPP1142172), Wellcome Trust (202912/Z/16/Z), the Brazilian Health Surveillance Secretariat,
297 Ministry of Health, Bahia State, Research Support Foundation of the State of Bahia (FAPESB), the
298 Research and Project Funding Agency (FINEP), and the Secretariat of Science and Technology of the
299 State of Bahia (SECTI). Dr Paixão is a fellow supported by the Wellcome Trust (213589/Z/18/Z).

300 **Competing Interests**

301 None declared.

302 **Patient Consent for Publication**

303 Not required.

304 **Data Availability Statement**

305 Data is freely available without restriction at <https://opendatasus.saude.gov.br/dataset/bd-srag-2020>.

306 Code book and analytic code will be made available upon request from the corresponding author.

References

1. World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard. <https://covid19.who.int/>. Accessed May 13, 2020.
2. Centers for Disease Control and Prevention. Coronavirus Disease 2019 (COVID-19). People Who Are at Increased Risk for Severe Illness. <https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-at-increased-risk.html>. Accessed July 21, 2020.
3. Liu H, Chen S, Liu M, Nie H, Lu H. Comorbid Chronic Diseases are Strongly Correlated with Disease Severity among COVID-19 Patients: A Systematic Review and Meta-Analysis. *Aging Dis*. 2020;11(3):668-678. doi:10.14336/ad.2020.0502.
4. Alberca RW, Oliveira LM, Branco ACCC, Pereira NZ, Sato MN. Obesity as a risk factor for COVID-19: an overview [published online June 15, 2020]. *Crit Rev Food Sci Nutr*. doi:10.1080/10408398.2020.1775546.
5. Sattar N, McInnes IB, McMurray JJV. Obesity Is a Risk Factor for Severe COVID-19 Infection: Multiple Potential Mechanisms. *Circulation*. 2020;142(1):4-6. doi:10.1161/circulationaha.120.047659.
6. Caussy C, Wallet F, Laville M, Disse E. Obesity is Associated with Severe Forms of COVID-19. *Obesity (Silver Spring)*. 2020;28(7):1175. doi:10.1002/oby.22842.
7. Li Q, Guan X, Wu P, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. *N Engl J Med*. 2020;382(13):1199-1207. doi:10.1056/nejmoa2001316.
8. Grasselli G, Zangrillo A, Zanella A, et al. Baseline Characteristics and Outcomes of 1591 Patients Infected with SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. *JAMA*. 2020;323(16):1574-1581. doi:10.1001/jama.2020.5394.
9. Caussy C, Pattou F, Wallet F, et al. Prevalence of obesity among adult inpatients with COVID-19 in France. *Lancet Diabetes Endocrinol*. 2020;8(7):562-564. doi:10.1016/s2213-8587(20)30160-1.
10. Hernández-Garduño E. Obesity is the comorbidity more strongly associated for Covid-19 in Mexico. A case-control study. *Obes Res Clin Pract*. 2020;14(4):375-379. doi:10.1016/j.orcp.2020.06.001.
11. Hajifathalian K, Kumar S, Newberry C, et al. Obesity is associated with worse outcomes in COVID-19: Analysis of Early Data From New York City. *Obesity (Silver Spring)*. 2020;28(9):1606-1612. doi:10.1002/oby.22923.
12. Lighter J, Phillips M, Hochman S, et al. Obesity in patients younger than 60 years is a risk factor for Covid-19 hospital admission. *Clin Infect Dis*. 2020;71(15):896-897. doi:10.1093/cid/ciaa415.
13. Bello-Chavolla OY, Bahena-López JP, Antonio-Villa NE, et al. Predicting Mortality Due to SARS-CoV-2: A Mechanistic Score Relating Obesity and Diabetes to COVID-19 Outcomes in Mexico. *J Clin Endocrinol Metab*. 2020;105(8):dgaa346. doi:10.1210/clinem/dgaa346.
14. Simonnet A, Chetboun M, Poissy J, et al. High Prevalence of Obesity in Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Requiring Invasive Mechanical Ventilation. *Obesity (Silver Spring)*. 2020;28(7):1195-1199. doi:10.1002/oby.22831.
15. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128.9 million children, adolescents, and adults. *Lancet*. 2017;390(10113):2627-2642. doi:10.1016/s0140-6736(17)32129-3.
16. GBD 2015 Obesity Collaborators. Health Effects of Overweight and Obesity in 195 Countries over 25 Years. *N Engl J Med*. 2017;377(1):13-27. doi:10.1056/nejmoa1614362.
17. Brasil. Ministério da Saúde. Vigitel Brasil 2018: vigilância de fatores de risco e proteção para doenças crônicas por inquérito telefônico. Brasília, DF: Ministério da Saúde; 2019. <https://portalquivos2.saude.gov.br/images/pdf/2019/julho/25/vigitel-brasil-2018.pdf>. Accessed July 10, 2020.

18. GBD 2016 Brazil Collaborators. Burden of disease in Brazil, 1990-2016: a systematic subnational analysis for the Global Burden of Disease Study 2016. *Lancet*. 2018;392(10149):760-775. doi:10.1016/s0140-6736(18)31221-2.
19. Flint SW, Tahrani AA. COVID-19 and obesity-lack of clarity, guidance, and implications for care. *Lancet Diabetes Endocrinol*. 2020;8(6):474-475. doi:10.1016/s2213-8587(20)30156-x.
20. Brasil. Ministério da Saúde. Severe Acute Respiratory Syndrome dataset - including COVID-19 data. 2020. <https://opendatasus.saude.gov.br/dataset/bd-srag-2020>. Accessed July 11, 2020.
21. World Health Organization. Physical status: the use and interpretation of anthropometry. Geneva: WHO; 1995. <https://apps.who.int/iris/handle/10665/37003>. Accessed July 11, 2020.
22. Organización Panamericana de la Salud. División de Promoción y Protección de la Salud (HPP). Encuesta sobre Salud, Bienestar y Envejecimiento (SABE) en América Latina el Caribe: Informe Preliminar (Internet). In: XXXVI Reunión del Comité asesor de investigaciones em Salud; 9-11 jun 2001; Kingston: OPAS, 2002. <http://envejecimiento.csic.es/documentos/documentos/paho-salud-01.pdf>. Accessed July 11, 2020.
23. Brasil. Ministério da Saúde. Guidelines for the Collection and Analysis of Anthropometric Data in Health Services. Technical Standard for the Food and Nutrition Surveillance System. Brasília, DF: Ministério da Saúde; 2011.
24. Cheng FW, Gao X, Mitchell DC, et al. Body mass index and all-cause mortality among older adults. *Obesity (Silver Spring)*. 2016;24(10):2232-39. doi:10.1002/oby.21612.
25. Honce R, Schultz-Cherry S. Impact of Obesity on Influenza A Virus Pathogenesis, Immune Response, and Evolution. *Front Immunol*. 2019;10:1071. doi:10.3389/fimmu.2019.01071.
26. Puig-Domingo M, Marazuela M, Giustina A. COVID-19 and endocrine diseases. A statement from the European Society of Endocrinology. *Endocrine*. 2020;68(1):2-5. doi:10.1007/s12020-020-02294-5.
27. Docherty AB, Harrison EM, Green CA, et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. *BMJ*. 2020;369:m1985. doi:10.1136/bmj.m1985.
28. Fernández-Niño JA, Guerra-Gómez JA, Idrovo AJ. Multimorbidity patterns among COVID-19 deaths: proposal for the construction of etiological models. *Rev Panam Salud Publica*. 2020;44:e166. doi:10.26633/RPSP.2020.166.
29. Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using OpenSAFELY. *Nature*. 2020;584(7821):430-436. doi:10.1038/s41586-020-2521-4.
30. Klang E, Kassim G, Soffer S, et al. Morbid Obesity as an Independent Risk Factor for COVID-19 Mortality in Hospitalized Patients Younger than 50. *Obesity (Silver Spring)*. 2020;28(9):1595-1599. doi:10.1002/oby.22913.
31. Cantarino L, Merchan-Hamann E. Influenza in Brazil: surveillance pathways. *J Infect Dev Ctries*. 2016;10(1):13-23. doi:10.3855/jidc.7135.
32. de Souza WM, Buss LF, Candido DDS, et al. Epidemiological and clinical characteristics of the COVID-19 epidemic in Brazil. *Nat Hum Behav*. 2020;4(8):856-865. doi:10.1038/s41562-020-0928-4.
33. Baqui P, Bica I, Marra V, Ercole A, van der Schaar M. Ethnic and regional variations in hospital mortality from COVID-19 in Brazil: a cross-sectional observational study. *Lancet Glob Health*. 2020;8(8):e1018-e1026. doi: 10.1016/S2214-109X(20)30285-0.

Figure legends

Figure 1. Selection of the study population from SIVEP-Gripe.

SIVEP-Gripe: Influenza Epidemiological Surveillance Information System.

Table 1. Demographic characteristics, comorbidities, hospitalization outcomes and death according to the combined exposure of obesity, diabetes, and/or cardiovascular diseases in adults with severe COVID-19.

	Total		None		OB		OB + DM and/or CVD		DM and/or CVD	
	n	%	n	%	n	%	n	%	n	%
Overall	8848	100.0	3161	35.7	409	4.6	452	5.1	4826	54.6
Sex										
Female	3774	42.7	1511	40.0	165	4.4	199	5.3	1899	50.3
Male	5074	57.4	1650	32.5	244	4.8	253	5.0	2927	57.7
Age										
< 40 years	1976	22.3	1064	53.9	188	9.5	102	5.2	622	31.5
≥ 40 years	6872	77.7	2097	30.5	221	3.2	350	5.1	4204	61.2
Chronic pulmonary disease										
No	8502	96.1	2969	34.9	388	4.6	435	5.1	4710	55.4
Yes	346	3.9	192	55.5	21	6.1	17	4.9	116	33.5
Asthma										
No	8184	92.5	2728	33.3	383	4.7	414	5.1	4659	56.9
Yes	664	7.5	433	65.2	26	3.9	38	5.7	167	25.2
Chronic kidney disease										
No	8297	93.8	2958	35.7	399	4.8	434	5.2	4506	54.3
Yes	551	6.2	203	36.8	10	1.8	18	3.3	320	58.1
Chronic hematologic disease										
No	8710	98.4	3081	35.4	406	4.7	445	5.1	4778	54.9
Yes	138	1.6	80	58.0	3	2.2	7	5.1	48	34.8
Chronic neurological disease										
No	8588	97.1	3014	35.1	406	4.7	442	5.2	4726	55.0
Yes	260	2.9	147	56.5	3	1.2	10	3.9	100	38.5
Chronic liver disease										
No	8684	98.2	3083	35.5	406	4.7	443	5.1	4752	54.7
Yes	164	1.9	78	47.6	3	1.8	9	5.5	74	45.1
Immunosuppression										
No	8276	93.5	2777	33.6	393	4.8	440	5.3	4666	56.4
Yes	572	6.5	384	67.1	16	2.8	12	2.1	160	28.0
Mechanical ventilation*										
No	2727	33.8	1144	42.0	93	3.4	88	3.2	1402	51.4
Non-invasive	3634	45.0	1178	32.4	192	5.3	190	5.2	2074	57.1
Invasive	1714	21.2	529	30.9	101	5.9	150	8.8	934	54.5
ICU admission*										
No	5438	64.6	2025	37.2	235	4.3	222	4.1	2956	54.4
Yes	2976	35.4	1007	33.8	163	5.5	216	7.3	1590	53.4
Death*										
No	4525	68.9	1699	37.6	211	4.7	200	4.4	2415	53.4
Yes	2040	31.1	640	31.4	92	4.5	140	6.9	1168	57.3

OB: obesity (BMI \geq 30 kg/m²), DM: diabetes mellitus, CVD: cardiovascular disease, ICU: intensive care unit.

* Mechanical ventilation (n=8075), ICU admission (n=8414), and death (n=6565).

Table 2. Demographic characteristics, comorbidities, hospitalization outcomes and death according to the combined exposure of obesity, diabetes, and/or cardiovascular diseases in elders with severe COVID-19.

	Total		None		OB		OB + DM and/or CVD		DM and/or CVD	
	n	%	n	%	n	%	n	%	n	%
Overall	12925	100.0	2837	21.9	91	0.7	358	2.8	9639	74.6
Sex										
Female	5968	46.2	1232	20.6	52	0.9	209	3.5	4475	75.0
Male	6957	53.8	1605	23.1	39	0.6	149	2.1	5164	74.2
Age										
< 80 years	9355	72.4	2011	21.5	77	0.8	309	3.3	6958	74.4
≥ 80 years	3570	27.6	826	23.1	14	0.4	49	1.4	2681	75.1
Chronic pulmonary disease										
No	11885	92.0	2494	21.0	85	0.7	325	2.7	8981	75.6
Yes	1040	8.1	343	33.0	6	0.6	33	3.2	658	63.3
Asthma										
No	12474	96.5	2687	21.5	90	0.7	336	2.7	9361	75.0
Yes	451	3.5	150	33.3	1	0.2	22	4.9	278	61.6
Chronic kidney disease										
No	11882	91.9	2608	22.0	85	0.7	311	2.6	8878	74.7
Yes	1043	8.1	229	22.0	6	0.6	47	4.5	761	73.0
Chronic hematologic disease										
No	12728	98.5	2751	21.6	91	0.7	354	2.8	9532	74.9
Yes	197	1.5	86	43.7	0	0.0	4	2.0	107	54.3
Chronic neurological disease										
No	11871	91.9	2511	21.2	89	0.8	338	2.9	8933	75.3
Yes	1054	8.2	326	30.9	2	0.2	20	1.9	706	67.0
Chronic liver disease										
No	12734	98.5	2777	21.8	87	0.7	353	2.8	9517	74.7
Yes	191	1.5	60	31.4	4	2.1	5	2.6	122	63.9
Immunosuppression										
No	12303	95.2	2558	20.8	87	0.7	342	2.8	9316	75.7
Yes	622	4.8	279	44.9	4	0.6	16	2.6	323	51.9
Mechanical ventilation*										
No	2725	23.0	626	23.0	18	0.7	70	2.6	2011	73.8
Non-invasive	5557	47.0	1164	21.0	38	0.7	141	2.5	4214	75.8
Invasive	3547	30.0	767	21.6	29	0.8	133	3.8	2618	73.8
ICU admission*										
No	6898	56.4	1578	22.9	41	0.6	168	2.4	5111	74.1
Yes	5324	43.6	1107	20.8	44	0.8	181	3.4	3992	75.0
Death*										
No	3684	37.1	823	22.3	21	0.6	95	2.6	2745	74.5
Yes	6259	63.0	1407	22.5	43	0.7	173	2.8	4636	74.1

OB: obesity (BMI \geq 30 kg/m²), DM: diabetes mellitus, CVD: cardiovascular disease, ICU: intensive care unit.

* Mechanical ventilation (n=11829), ICU admission (n=12222), and death (n=9943).

Table 3. Combined association of obesity, diabetes, and/or cardiovascular disease with non-invasive and invasive mechanical ventilation use, intensive care unit admission, and death in adult and elderly patients hospitalized with severe COVID-19.

Main exposure variable		Non-invasive mechanical ventilation*				Invasive mechanical ventilation*			
		Crude model		Adjusted model #		Crude model		Adjusted model #	
		PR	95%CI	PR	95%CI	PR	95%CI	PR	95%CI
Adults 20-59 years	None	1.00		1.00		1.00		1.00	
	OB	2.00	1.54-2.60	2.13	1.64-2.78	2.35	1.74-3.17	2.69	1.98-3.65
	OB + DM and/or CVD	2.10	1.61-2.73	2.06	1.58-2.69	3.69	2.78-4.89	3.76	2.82-5.01
	DM and/or CVD	1.44	1.29-1.60	1.35	1.20-1.51	1.44	1.26-1.64	1.32	1.14-1.52
Elders ≥ 60 years	None	1.00		1.00		1.00		1.00	
	OB	1.14	0.64-2.01	1.22	0.69-2.16	1.31	0.72-2.39	1.43	0.78-2.61
	OB + DM and/or CVD	1.08	0.80-1.47	1.15	0.84-1.55	1.55	1.14-2.11	1.66	1.22-2.27
	DM and/or CVD	1.13	1.01-1.26	1.14	1.01-1.27	1.06	0.94-1.20	1.10	0.97-1.24
		ICU admission**				Death***			
		Crude model		Adjusted model #		Crude model		Adjusted model #	
		PR	95%CI	PR	95%CI	PR	95%CI	PR	95%CI
Adults 20-59 years	None	1.00		1.00		1.00		1.00	
	OB	1.23	1.08-1.40	1.31	1.13-1.53	1.11	0.92-1.33	1.33	1.05-1.69
	OB + DM and/or CVD	1.48	1.33-1.65	1.60	1.40-1.83	1.50	1.30-1.74	1.79	1.45-2.21
	DM and/or CVD	1.05	0.99-1.12	1.03	0.95-1.12	1.19	1.10-1.29	1.16	1.03-1.30
Elders ≥ 60 years	None	1.00		1.00		1.00		1.00	
	OB	1.26	1.02-1.55	1.40	1.07-1.82	1.06	0.89-1.27	1.67	1.00-2.80
	OB + DM and/or CVD	1.26	1.13-1.41	1.37	1.19-1.59	1.02	0.93-1.12	1.39	1.07-1.80
	DM and/or CVD	1.06	1.01-1.12	1.11	1.04-1.18	1.00	0.96-1.03	1.05	0.95-1.16

OB: obesity ($BMI \geq 30 \text{ kg/m}^2$), DM: diabetes mellitus, CVD: cardiovascular disease, ICU: intensive care unit, PR: prevalence ratio, 95%CI: 95% confidence interval.

* Crude and adjusted multinomial logistic regression models for mechanical ventilation use in adults (n=8075) and elders (n=11829).

** Crude and adjusted logistic regression models for ICU admission in adults (n= 8414) and elders (n=12222).

*** Crude and adjusted logistic regression models for death in adults (n=6565) and elders (n=9943).

Adjusted for sex, age in years, pulmonary disease, asthma, kidney disease, hematologic disease, neurological disease, liver disease, and immunosuppression.

Table 4. Independent association of degrees of obesity with non-invasive and invasive mechanical ventilation, intensive care unit admission, and death in hospitalized adults with severe COVID-19.

Main exposure variable	Non-invasive mechanical ventilation*				Invasive mechanical ventilation*			
	Crude model		Adjusted model #		Crude model		Adjusted model #	
	PR	95%CI	PR	95%CI	PR	95%CI	PR	95%CI
No obesity (< 30 kg/m ²)	1.00		1.00		1.00		1.00	
Obesity class I (≥ 30-34.9 kg/m ²)	1.78	1.35-2.33	1.91	1.45-2.51	2.59	1.93-3.47	3.00	2.22-4.05
Obesity class II (≥ 35-39.9 kg/m ²)	1.44	1.04-2.00	1.58	1.14-2.19	2.10	1.47-2.99	2.47	1.72-3.54
Obesity class III (≥ 40 kg/m ²)	1.70	1.19-2.44	1.88	1.31-2.69	2.51	1.71-3.70	3.00	2.03-4.45
	ICU admission**				Death**			
	Crude model		Adjusted model #		Crude model		Adjusted model #	
	PR	95%CI	PR	95%CI	PR	95%CI	PR	95%CI
No obesity (< 30 kg/m ²)	1.00		1.00		1.00		1.00	
Obesity class I (≥ 30-34.9 kg/m ²)	1.31	1.17-1.47	1.42	1.23-1.64	1.11	0.94-1.31	1.32	1.05-1.66
Obesity class II (≥ 35-39.9 kg/m ²)	1.34	1.16-1.54	1.46	1.23-1.74	1.16	0.95-1.42	1.41	1.06-1.87
Obesity class III (≥ 40 kg/m ²)	1.32	1.14-1.54	1.45	1.20-1.74	1.33	1.10-1.59	1.77	1.35-2.33

Degrees of obesity defined by the WHO cutoff points.

PR: prevalence ratio, 95%CI: 95% confidence interval.

* Crude and adjusted multinomial logistic regression models for mechanical ventilation use (n=8075).

** Crude and adjusted logistic regression models for ICU admission (n=8414) and mortality (n=6565).

Adjusted for sex, age in years, diabetes mellitus, cardiovascular disease, pulmonary disease, asthma, kidney disease, hematologic disease, neurological disease, liver disease, and immunosuppression.

Eligible population
(patients hospitalized, aged ≥ 20 years,
positive for SARS-Cov2, and complete
demographic and comorbidity data)
n=21,942

Implausible information
Obesity (BMI): 169 (0.8%)

Study population
(inpatients aged ≥ 20 years, positive for
SARS-Cov2, and complete and plausible
demographic and comorbidity data)
Adults (20-59 years): 8,848
Elders (≥ 60 years): 12,925

Incomplete information
Mechanical ventilation: 1869 (8.6%)
ICU admission: 1137 (5.2%)
Death: 5265 (24.2%)

Mechanical ventilation use
Study population with complete
information for mechanical ventilation
Adults (20-59 years): 8,075
Elders (≥ 60 years): 11,829

ICU admission
Study population with complete
information for ICU admission
Adults (20-59 years): 8,414
Elders (≥ 60 years): 12,222

Death
Study population with complete
information for death
Adults (20-59 years): 6,565
Elders (≥ 60 years): 9,943